Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Pfizer heads to FDA with phase 3 myeloma win for Elrexfio

27 October 2026 · By · Wire by Fusion42

Published

27 October 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercepharma.com →

◆ Verified

Fusion42 · 27 October 2026 · Fusion42 review

Pfizer announced a phase 3 trial win for Elrexfio as a treatment for relapsed or refractory multiple myeloma after first-line therapy, showing significant improvement in progression-free survival compared to standard regimens. Pfizer plans to submit the data to global regulators to expand Elrexfio's label earlier in the treatment sequence, targeting a $1.32 billion market opportunity by 2032.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You are about to see a clearer path for Elrexfio entering earlier treatment for myeloma. If you build tools or services supporting clinical trial data or regulatory strategy, this shift opens new commercial doors.

◆ Coverage

1 source · 27 Oct 2026

◆ Related on Wire

◆ Topics

Biotechmyelomaclinical-trialdrug-approvalpharmaoncologyPfizer